The Acute Myeloid Leukemia Channel is supported through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe, MD, Ludwig-Maximilians-University Munich, Munich, Germany, presents emerging CAR T-cell therapies in acute myeloid leukemia (AML), including Phase Ia data from the RevSTAR-123 trial (NCT05949125) of AVC-201, a first-in-class CRISPR-engineered allogeneic switchable CD123-directed CAR T-cell therapy, in patients with relapsed/refractory (R/R) AML. Prof. Subklewe highlights the promising activity of AVC-201, noting robust CAR T-cell expansion and a manageable safety profile, with the trial continuing into the Phase Ib portion. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
